Breaking News

Tweet TWEET

NeuroMetrix Launches Second Generation SENSUS Device

  NeuroMetrix Launches Second Generation SENSUS Device

Business Wire

WALTHAM, Mass. -- March 18, 2014

NeuroMetrix, Inc. (the “Company”) (Nasdaq:NURO), an innovative health care
company that develops wearable medical technology and point-of-care
diagnostics that help patients and physicians better manage chronic pain,
nerve disorders, and associated sleep disturbances, today reported first
shipments of the second generation of its wearable therapeutic technology, the
SENSUS^™  Pain Management System.

SENSUS technology utilizes comfortable, non-invasive electrical nerve
stimulation of sensory nerves to induce a safe and effective elevation in the
level of naturally occurring neuromodulatory chemicals, called enkephalins,
which block the transmission of pain signals throughout the nervous system. As
a result, many patients experience fast-acting, non-narcotic relief from
chronic pain when using SENSUS.

SENSUS is a transcutaneous electrical nerve stimulator with broad regulatory
indications for management of chronic pain and is the only such device cleared
by the FDA specifically for use during sleep. The device is lightweight and
can be worn during the day while remaining active, and at night while
sleeping. It incorporates a tri-axial MEMS accelerometer that monitors patient
body position and movement enabling automatic regulation of therapeutic
parameters.

The device is designed for people with diabetes that suffer from chronic pain.
The most common cause of such pain is painful diabetic neuropathy (PDN), which
affects up to 5 million people in the U.S. alone. Additional forms of chronic
pain that may benefit from transcutaneous electrical nerve stimulation include
fibromyalgia, post herpetic neuropathy (shingles), and conditions with both
chronic pain and disturbed sleep such as restless leg syndrome.

The second-generation SENSUS builds on the successful launch of the technology
in early 2013. Over 2000 first generation devices have shipped since launch.
The second-generation device is about 20% thinner and has several key hardware
improvements. The thinner design makes the device more discreet when worn
under clothing and more comfortable during sleep.

“The launch of our second generation SENSUS device demonstrates our scientific
capabilities in wearable medical technology and commitment to continual
innovation. Feedback from patients and physicians on the over 2000 first
generation devices in use has been positive and provided us with a road-map
for further improvements, many of which are incorporated into the second
generation device,” said Shai N. Gozani, M.D., Ph.D., President and Chief
Executive Officer of NeuroMetrix. “In addition to the use of SENSUS in
managing chronic pain, the novel integration of electrical stimulation and
activity tracking through the embedded accelerometer offers exciting
opportunities to develop wearable therapeutic devices for a variety of medical
conditions.”

About NeuroMetrix

NeuroMetrix is an innovative health-care company that develops wearable
medical technology and point-of-care diagnostics that help patients and
physicians better manage chronic pain, nerve disorders, and associated sleep
disturbances. The Company has a major focus on diabetic neuropathies, which
affect over 50% of people with diabetes. If left untreated, diabetic
neuropathies trigger foot ulcers that may require amputation and cause
disabling chronic pain. The annual cost of diabetic neuropathies has been
estimated at $14 billion in the United States. The company markets the
SENSUS^™ Pain Management System for treating chronic pain, focusing on
physicians managing patients with painful diabetic neuropathy and other forms
of chronic pain such as fibromyalgia, post herpetic neuropathy (shingles), and
conditions with both chronic pain and disturbed sleep such as restless leg
syndrome. The company also markets the DPNCheck^® device, which is a rapid,
accurate, and quantitative point-of-care test for peripheral neuropathies such
as diabetic neuropathy. This product is used to detect neuropathies at an
early stage and to guide treatment. For more information, please visit
http://www.NeuroMetrix.com.

Contact:

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
 
Press spacebar to pause and continue. Press esc to stop.